Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines

  • Pakeezah Saadat
  • , Nick Bansback
  • , Marie Falahee
  • , Mickael Hiligsmann
  • , Peter Tugwell
  • , Rachelle Buchbinder
  • , Samuel Whittle
  • , Dawn P. Richards
  • , Laurie Proulx
  • , Holger Schunemann
  • , Pablo Alonso-Coello
  • , Robby Nieuwlaat
  • , Wojtek Wiercioch
  • , Simon Kuper
  • , Jordi Pardo Pardo
  • , Glen Hazlewood*
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction The pharmacological management of inflammatory arthritis often requires choices that involve trade-offs between benefits, risks and other attributes such as administration route, frequency and cost. This living systematic review aims to inform international clinical guidelines on inflammatory arthritis by creating an evidence map of patient preference studies concerning the trade-offs in pharmacological management of inflammatory arthritis.Methods and analysis We will include published and peer-reviewed full-text studies in any language that quantitatively assess preferences of patients for the pharmacological management of inflammatory arthritis (rheumatoid arthritis, spondyloarthritis and juvenile idiopathic arthritis). Studies must use either stated or revealed preference methods to assess preferences and provide a quantitative assessment of relevant characteristics, such as benefits, risks, costs and process attributes. Articles will identified through Medline and EMBASE database searches from inception using search terms that combine keywords and subject headings for inflammatory arthritis and preference-based methods, and a search in the Health Preference Study and Technology Registry using keywords for the populations of interest. Two independent reviewers will perform abstract and full-text screening. Risk of bias will be assessed using the GRADE risk of bias tool. An evidence map will be generated to summarise included studies and their assessments of each trade-off. The search will be conducted every 6 months with new studies added to the inventory.Ethics and dissemination Ethics approval is not required. Results from the base review will be published in a peer-reviewed journal and findings will be presented at conferences. In the living model, we will publish updates and datasets on an Open Science Framework page, with periodic updates in peer-reviewed journals.
Original languageEnglish
Article numbere088267
Number of pages7
JournalBMJ Open
Volume15
Issue number1
DOIs
Publication statusPublished - 15 Jan 2025

Keywords

  • Patients
  • RHEUMATOLOGY
  • Systematic Review

Fingerprint

Dive into the research topics of 'Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines'. Together they form a unique fingerprint.

Cite this